Patents by Inventor Didier Jean-Claude Berthelot

Didier Jean-Claude Berthelot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20220315557
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: October 6, 2022
    Inventors: Tianbao LU, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • PYRIDINE RINGS CONTAINING DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20220162187
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein the variables are defined herein.
    Type: Application
    Filed: April 10, 2020
    Publication date: May 26, 2022
    Inventors: Johannes Wilhelmus J. THURING, Tianbao LU, Tongfei WU, Gaston Stanislas M. DIELS, Didier Jean-Claude BERTHELOT, Berthold WROBLOWSKI
  • (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
    Patent number: 11267804
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
    Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10954214
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10898504
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Brian Christopher Shook, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Tongfei Wu, Lieven Meerpoel
  • Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
    Patent number: 10894793
    Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 19, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Olivier Alexis Georges Querolle
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10888550
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 12, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Didier Jean-Claude Berthelot, Tongfei Wu
  • NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200289539
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 17, 2020
    Inventors: Didier Jean-Claude BERTHELOT, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Ronaldus Arnodus Hendrika Joseph GILISSEN, Edward Charles LAWSON, Vineet PANDE, Marcus Cornells Bernardus Catbarina PARADE, Wim Bert Griet SCHEPENS, Brian Christopher SHOOK, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE, Weimei SUN, Tongfei WU, Lieven MEERPOEL
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS
    Publication number: 20200181132
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 11, 2020
    Inventors: Patrick Rene Angibaud, Olivier, Alexis Georges QUEROLLE, Didier Jean-Claude BERTHELOT, Christophe MEYER, Matthieu Philippe, Victor WILLOT, Lieven MEERPOEL, Thierry, François Alain, Jean JOUSSEAUME
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS
    Publication number: 20200079763
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 12, 2020
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Quinoxaline and pyridopyrazine derivatives as PI3K? inhibitors
    Patent number: 10526316
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20190381012
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Inventors: Tianbao LU, Peter J. CONNOLLY, Maxwell David CUMMINGS, Gaston Stanislas Marcella DIELS, Jan Willem THURING, Ulrike PHILIPPAR, James Patrick EDWARDS, Didier Jean-Claude BERTHELOT, Tongfei WU
  • AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS
    Publication number: 20190263804
    Abstract: The present invention relates to azabenzimidazole derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: June 15, 2017
    Publication date: August 29, 2019
    Inventors: Isabelle Noelle Constance Pilatte, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquier, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Didier Jean-Claude Berthelot
  • BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS
    Publication number: 20190169199
    Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: June 15, 2017
    Publication date: June 6, 2019
    Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Birgine Sophie Poncelet, Olivier Alexis Georges Querolle
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20190062311
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 28, 2019
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors
    Patent number: 10202387
    Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 12, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Imidazopyridazine derivatives as PI3KB inhibitors
    Patent number: 10087187
    Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Macrocylic pyrimidine derivatives
    Patent number: 10017509
    Abstract: The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: July 10, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gaston Stanislas Marcella Diels, Bruno Schoentjes, Matthias Luc Aime Versele, Didier Jean-Claude Berthelot, Marc Willems, Marcel Viellevoye, Werner Constant Johan Embrechts, Berthold Wroblowski, Lieven Meerpoel
  • HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20180057496
    Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 1, 2018
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey